[
    [
        {
            "time": "",
            "original_text": "【药明康德|一季报点评】基本面强劲的CXO行业巨头【安信医药】",
            "features": {
                "keywords": [
                    "药明康德",
                    "一季报",
                    "CXO",
                    "基本面强劲",
                    "安信医药"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "CXO"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【药明康德|一季报点评】基本面强劲的CXO行业巨头【安信医药】",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "被高瓴看好医药外包行业具备诞生世界龙头的潜力（附股）",
            "features": {
                "keywords": [
                    "高瓴",
                    "医药外包",
                    "世界龙头",
                    "潜力"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "外包"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "被高瓴看好医药外包行业具备诞生世界龙头的潜力（附股）",
                "Correlation": 7,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "药明康德（603259）：业绩维持稳健增长，长期发展动力充足【2020年一季报点评|西南医药朱国广/杜向阳团队】",
            "features": {
                "keywords": [
                    "药明康德",
                    "业绩稳健增长",
                    "长期发展动力",
                    "一季报",
                    "西南医药"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "药明康德（603259）：业绩维持稳健增长，长期发展动力充足【2020年一季报点评|西南医药朱国广/杜向阳团队】",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "国际药企受疫情影响暂缓研发计划 国内CRO公司复工复产或迎发展良机",
            "features": {
                "keywords": [
                    "国际药企",
                    "疫情影响",
                    "研发计划",
                    "CRO",
                    "复工复产",
                    "发展良机"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "CRO"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "国际药企受疫情影响暂缓研发计划 国内CRO公司复工复产或迎发展良机",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        }
    ]
]